MARKET

CAPR

CAPR

Capricor Therapeutics Inc
NASDAQ
4.375
+0.135
+3.18%
Opening 12:47 01/30 EST
OPEN
4.200
PREV CLOSE
4.240
HIGH
4.460
LOW
4.200
VOLUME
51.58K
TURNOVER
108.16K
52 WEEK HIGH
6.58
52 WEEK LOW
2.810
MARKET CAP
110.43M
P/E (TTM)
-3.8676
1D
5D
1M
3M
1Y
5Y
Capricor stock falls amid data for duchenne muscular dystrophy study
Seeking Alpha · 5d ago
Intuitive Surgical, Fisker, Li-Cycle Holdings among premarket losers' pack
Seeking Alpha · 5d ago
Capricor Therapeutics Announces 18-Month Results From Ongoing HOPE-2 Open Label Extension Study Of CAP-1002 In Duchenne Muscular Dystrophy Patients
Benzinga · 5d ago
Capricor Therapeutics' Duchenne Muscular Dystrophy Therapy Meets Primary Endpoint at One-Year Mark
Capricor Therapeutics' Duchenne Muscular Dystrophy Therapy Meets Primary Endpoint at One-Year Mark
MT Newswires · 5d ago
BRIEF-Capricor Therapeutics And Parent Project Muscular Dystrophy To Host Webinar
Reuters · 01/19 21:06
Capricor Highlights Preclinical Data From Its Closed COVID-19 Vaccine Study
Benzinga · 01/12 17:55
BRIEF-Capricor Therapeutics Inc Announces Publication Highlighting New Advances For Its Engineered Exosome Platform
Reuters · 01/12 14:36
Capricor Announces Publication Highlighting New Advances For Its Engineered Exosome Platform
Benzinga · 01/12 14:29
More
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company that is focused on developing transformative cell and exosome-based therapeutics and vaccines for treating and preventing a broad spectrum of diseases. The Company consists of cell therapy program, including CAP-1002 for Duchenne Muscular Dystrophy program and CAP-1002 with CAP-1002 for coronavirus (COVID-19). The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology therapeutic platform. The Company is focused on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA) as well as proteins, to treat or prevent a range of diseases. CAP-1002 cell therapy programs initiated Pivotal Phase III, HOPE-3.

Webull offers kinds of Capricor Therapeutics Inc stock information, including NASDAQ:CAPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CAPR stock methods without spending real money on the virtual paper trading platform.